BETHESDA, Md.--(Business Wire)--
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that its
presentation at the 2009 Annual Credit Suisse Health Care Conference will be
webcast and may be accessed at www.sucampo.com.
A member of Sucampo Pharmaceuticals` senior management team will present an
overview of the company on Wednesday, November 11, 2009, at 5 pm Mountain Time,
or 7 pm Eastern Time.
Investors interested in listening to the live webcast should log on before the
start time in order to download any software required. The archive of the
webcast will be available for several days after the live event.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., an international biopharmaceutical company based
in Bethesda, Maryland, focuses on the development and commercialization of
medicines based on prostones. The therapeutic potential of prostones, which are
bio-lipids that occur naturally in the human body, was first identified by Ryuji
Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals` Chairman and Chief Executive
Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno,
Ph.D., founding Chief Executive Officer and currently Advisor, International
Business Development.
Sucampo markets AMITIZA® (lubiprostone) 24 mcg in the U.S. for chronic
idiopathic constipation in adults and Amitiza 8 mcg in the U.S. to treat
irritable bowel syndrome with constipation in adult women. Sucampo also is
developing the drug for additional gastrointestinal disorders with large
potential markets. In April 2009, Sucampo acquired U.S. and Canadian rights to
Rescula®, an FDA-approved treatment for open-angle glaucoma and ocular
hypertension. Sucampo plans to re-launch Rescula in 2010, and to develop it for
additional ophthalmic indications. In addition, Sucampo has a robust pipeline of
compounds with the potential to target underserved diseases affecting millions
of patients worldwide.
Sucampo Pharmaceuticals, Inc. has three wholly owned subsidiaries: Sucampo
Pharma Europe, Ltd., located in the UK; Sucampo Pharma, Ltd., located in Japan;
and, Sucampo Pharma Americas, Inc., located in Maryland. To learn more about
Sucampo Pharmaceuticals and its products, visit www.sucampo.com.
Amitiza is a registered trademark of Sucampo Pharmaceuticals, Inc. and Rescula
is a registered trademark used under license.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and
prospects for Sucampo Pharmaceuticals are forward-looking statements made under
the provisions of The Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the words "project," "believe,"
"anticipate," "plan," "expect," "estimate," "intend," "should," "would,"
"could," "will," "may" or other similar expressions. Forward-looking statements
include statements about the potential utility of Amitiza and Rescula to treat
particular indications and expected trial commencement, regulatory and launch
dates. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors, including
those described in Sucampo Pharmaceuticals` filings with the Securities and
Exchange Commission (SEC), including the annual report on Form 10-K for the year
ended December 31, 2008 and other periodic reports filed with the SEC. Any
forward-looking statements in this press release represent Sucampo
Pharmaceuticals` views only as of the date of this release and should not be
relied upon as representing its views as of any subsequent date. Sucampo
Pharmaceuticals does not undertake any obligation to update any forward-looking
statements contained in this release as a result of new information, future
events or otherwise, except as required by law.
Sucampo Pharmaceuticals, Inc.
Kate de Santis
240-223-3834
or
Westwicke Partners
John Woolford
410-213-0506
Copyright Business Wire 2009
